Dexmedetomidine Dosage for Postoperative Delirium and Cognitive Function in Elderly TKA Patients
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 132 people enrolled
- Started
- 1 Jul 2024
- Ended
- 1 Nov 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidine Injection [Precedex]
- Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
- Normal saline
- Record updated
- 26 November 2024
Who can take part
- Age
- 35 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients with Severe chronic knee osteoarthritis inducing limitation of movement and required knee replacements
- Patients of American Society of Anesthesiologists Classification grades II-III
- Patients free of exclusion criteria
Who cannot take part
- Patients had a history of uncompensated cardiac, renal, or hepatic diseases
- Patients had uncontrolled diabetes mellitus or hypertension
- Patients had local bone disorders that may prevent prosthesis stability
- Patients had allergies or contraindications to the study drugs
- Patients had autoimmune disease, coagulopathy, severe anemia with a hemoglobin concentration of <7 g%
- Patients of American Society of Anesthesiologists Classification grade >III
- Patients show a high risk for getting Post Operative Delirium or have severe cognitive dysfunction
- Patients had other causes for limited movement
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the efficacy of dexmedetomidine in reducing the incidence of postoperative delirium and cognitive dysfunction in elderly patients undergoing total knee arthroplasty (TKA). The study will compare the outcomes of patients receiving dexmedetomidine to those receiving a standard anesthetic or sedative, focusing on factors such as patient characteristics, surgical duration, and postoperative care. The research will explore the potential neuroprotective effects of dexmedetomidine and its ability to mitigate the risks associated with anesthesia and surgery in vulnerable elderly populations.
The 4 groups in the trial
- Control GroupPlacebo, for comparison
Treatment: Normal saline
- Group D-1Existing treatment, for comparison
Treatment: Dexmedetomidine Injection [Precedex] and Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
- Group D-2Existing treatment, for comparison
Treatment: Dexmedetomidine Injection [Precedex] and Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
- Group D-3Existing treatment, for comparison
Treatment: Dexmedetomidine Injection [Precedex] and Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimal Effective Dose of Dexmedetomidine on Postoperative Delirium and Cognitive Function of Elderly Patients Planned For TKA Surgery
- Record updated
- 26 November 2024